Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
An independent, anonymous patient survey program — publishing methodology before the first survey ships, so readers can audit our approach.
FDA labels, prescribing information, and Phase 3 trials describe the medications. They do not describe the actual patient journey: which provider, what the bill looked like at month 3, which side effect made someone switch, how long a refill actually took. Public sources (CDC, NIH, FDA) publish prescription counts and top-line trial data — not lived experience at the cost + telehealth interface.
We plan to fill that gap with independent, anonymous patient surveys — published alongside the existing public baselines so any reader can compare our findings to the established literature.
What patients THINK they will pay vs what they actually pay at month 3 and 6 — across brand, compounded, insurance, and cash pathways.
Why patients move between providers (price, side effects, communication, supply, refund handling). Provider-attributable churn signals.
Real-world rates of nausea, GI symptoms, fatigue, and discontinuation — vs the rates published in pivotal Phase 3 trials (STEP, SURMOUNT).
Time-to-prescription, refill friction, support responsiveness, lab work cadence, and prescriber availability across telehealth providers.
Sample size targets
N=300–500 per survey topic — large enough for stable subgroup analysis (brand vs compounded, insurance pathway, drug class).
Anonymous only — no PII
No name, email, address, DOB, or any unique identifier collected with survey responses. We do not link responses back to any user account on this site.
Voluntary + opt-out
Survey invitations are explicit, opt-in, and dismissible. Clear "this is research; do not share medical advice" disclosure on every screen.
Aggregate publication only
We publish summary statistics (means, medians, distributions). No per-respondent surfaces. No quotes attributed to identifiable individuals.
Comparison to public baselines
Every figure benchmarked against published NIH, CDC, FDA, or peer-reviewed reference data so readers can spot deviation.
Independent — no manufacturer funding
No funding, sponsorship, or in-kind support from drug manufacturers or telehealth providers. Conflicts disclosed on every published report.
Planned 2026 Q3 launch. Before the first survey ships, we need: privacy-lawyer review of the consent flow, anonymous-aggregation infrastructure (so individual responses cannot be re-identified from published summaries), and an independent ethics review reviewing the question set for risk of harm to respondents.
We are not a HIPAA covered entity and we will never collect PHI through these surveys. The infrastructure work is to ensure the same care applied to PHI is applied to research data anyway.
Editorial review, conflict-of-interest controls, and content review steps are documented in our comparison methodology and editorial policy. If you have a question about the survey methodology, email [email protected].
We'll email a one-time notice when the first survey opens — and publish each survey's aggregate findings via our weekly digest. Email only; no other PII collected.
See our scoring + verification methodology
Rubric, price-verification cadence, editor review steps, and conflict-of-interest controls.